Fundraising Fox
🦊/Companies
Sign in

Linnaeus Therapeutics

Haddonfield, US · Founded 2016 · 5 employees on LinkedIn · 3 known investors

Find your way into Linnaeus Therapeutics

118 people in our graph share verified history with the Linnaeus Therapeutics team — schools, employers, funds. One of them is your warm intro.

Brian Halakunlockedknows Patrick T. Mooney · together at Thomas Jefferson University (overlapped)
×4knows the team · via Thomas Jefferson University
×5knows the team · via Saint Joseph's University
knows the team · via Linnaeus Therapeutics
knows the team · via Thomas Weisel Partners

Clinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.

Biotech

Founders & leadership

PTPatrick T. Mooney
Patrick T. MooneyinExecutivePatrick T. Mooney is Chief Executive Officer of Linnaeus Therapeutics, a clinical-stage biotech company developing small molecule agents for cancer and pigmentation disorders. He studied medicine at Jefferson Medical College of Thomas Jefferson University and has worked in the biotechnology industry.

Board

JD
James DemetriadesBoard directorGeneral Partner at Kairos Venture Partners
TTTodd Thomson
Todd ThomsoninBoard directorChief Operating and Financial Officer at Kairos Venture Investments, Llc
MD
Michael D. PoiselBoard director
CA
Chris ArendtBoard director

Investors · 3

Kairos Venture Investments, LlcBeverly Hills · $150K – $20M
IA GlobalreportedAustin
Kairos Venture PartnersreportedBeverly Hills

Reported raises · per SEC filings

Form D private placements

$23.8M disclosed across 7 of 9 rounds · 2018–2026

▶$5MraisedApr 2026 · 26 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James DemetriadesDirector
  • Chris ArendtDirector
  • Todd ThomsonDirector
  • Patrick MooneyExecutive Officer, Director
  • John LeppingDirector
  • Michael PoiselDirector
Offering amount
$10M
Amount sold
$5M
Minimum investment
$1
First sale
Feb 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.3MraisedAug 2025 · 3 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • James DemetriadesDirector
  • Jack LeppingDirector
  • Michael PoiselDirector
  • Patrick T. MooneyExecutive Officer, Director
  • Chris ArendtDirector
  • Todd ThomsonDirector
Offering amount
$10M
Amount sold
$1.3M
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06c
Full filing on SEC EDGAR ↗
▶$5.8MraisedDec 2024 · 12 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick T. MooneyExecutive Officer
  • James DemetriadesDirector
  • Todd ThomsonDirector
  • Chris ArendtDirector
  • Michael D. PoiselDirector
Offering amount
$6.9M
Amount sold
$5.8M
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗
▶$3.1MraisedJan 2023 · 8 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick T. MooneyExecutive Officer, Director
  • Nicholas IatropoulosDirector
  • Todd ThomsonDirector
  • Michael D. PoiselDirector
Offering amount
$3.1M
Amount sold
$3.1M
Minimum investment
$15.7K
First sale
Jan 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗
▶$4.3MraisedAug 2021 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicholas IatropoulosDirector
  • Michael D. PoiselDirector
  • Patrick T. MooneyExecutive Officer, Director
  • Todd ThomsonDirector
Offering amount
$4.3M
Amount sold
$4.3M
Minimum investment
$25K
First sale
Aug 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗
▶$2.2MraisedFeb 2019 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Nicholas IatropoulosDirector
  • Patrick T. MooneyExecutive Officer, Director
  • Michael D. PoiselDirector
  • Christopher NataleExecutive Officer
Amount sold
$2.2M
Proceeds to insiders
$28.9K
First sale
Jan 2019
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗
▶$2.2MraisedSep 2018 · 4 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Christopher NataleExecutive Officer
  • Michael D. PoiselDirector
  • Nicholas IatropoulosDirector
  • Patrick T. MooneyExecutive Officer, Director
Amount sold
$2.2M
Proceeds to insiders
$100K
First sale
Aug 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b, 4a5
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Linnaeus Therapeutics raises $4.5M to launch melanoma trialtechnical.ly · Mar 2026Linnaeus Therapeutics Awarded Its Fourth Competitive SBIR Award by the National Cancer Institute Bringing Total SBIR Funding to $8.3 Millionprnewswire.com · Mar 2025Penn spinout Linnaeus Therapeutics secures an additional $1.6M in Funding - Penn Center for Innovationpci.upenn.edu · Nov 2024Linnaeus Therapeutics - Medtech Alertmedtechalert.com · Jan 2023Linnaeus Therapeutics Closes $12 Million Series B Financingprnewswire.com · Sep 2019

Frequently asked questions

What does Linnaeus Therapeutics do?
Clinical-stage biotech company developing small molecule agents modulating cellular differentiation for cancer and pigmentation disorders.
Who are Linnaeus Therapeutics's investors?
Linnaeus Therapeutics's investors include Kairos Venture Investments, Llc, IA Global, Kairos Venture Partners.
How much funding has Linnaeus Therapeutics raised?
Linnaeus Therapeutics has disclosed $23.8M raised across 7 of its 9 known rounds.
Where is Linnaeus Therapeutics headquartered?
Linnaeus Therapeutics is headquartered in Haddonfield, US.